XYREM
Total Payments
$3.5M
Transactions
11,960
Doctors
3,953
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $55,700 | 83 | 70 |
| 2023 | $152,663 | 121 | 43 |
| 2022 | $280,508 | 232 | 135 |
| 2021 | $170,195 | 100 | 84 |
| 2020 | $762,129 | 2,553 | 1,243 |
| 2019 | $2.1M | 8,871 | 3,354 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.5M | 84 | 43.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $882,333 | 347 | 25.3% |
| Consulting Fee | $444,431 | 128 | 12.7% |
| Food and Beverage | $290,487 | 10,558 | 8.3% |
| Travel and Lodging | $244,429 | 769 | 7.0% |
| Grant | $108,450 | 5 | 3.1% |
| Space rental or facility fees (teaching hospital only) | $7,500 | 2 | 0.2% |
| Education | $3,042 | 67 | 0.1% |
Payments by Type
General
$2.0M
11,876 transactions
Research
$1.5M
84 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| SODIUM OXYBATE IN REFRACTORY REM SLEEP BEHAVIOR DISORDER: A RANDOMIZED CONTROLLED STUDY | JAZZ PHARMACEUTICALS INC. | $405,183 | 0 |
| THE NEUROBEHAVIOURAL AND COGNITIVE EFFECTS OF DISRUPTED NIGHTTIME SLEEP IN PEDIATRIC NACOLEPSY | JAZZ PHARMACEUTICALS INC. | $134,820 | 0 |
| A MULTICENTER RETROSPECTIVE AND PROSPECTIVE FOLLOW-UP STUDY OF EARLY ONSET CHILDHOOD NARCOLEPSY: RECENT CASES AND POST INFECTION | JAZZ PHARMACEUTICALS INC. | $125,417 | 0 |
| A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED-WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF XYREM WITH AN OPEN-LABEL PHARMACOKINETIC EVALUATION AND SAFETY EXTENSION IN PEDIATRIC SUBJECTS WITH NARCOLEPSY WITH CATAPLEXY | JAZZ PHARMACEUTICALS INC. | $115,781 | 0 |
| THE NEUROBEHAVIORAL AND COGNITIVE EFFECTS OF DISRUPTED NIGHTTIME SLEEP IN PEDIATRIC NARCOLEPSY | JAZZ PHARMACEUTICALS INC. | $109,712 | 0 |
| UNDERSTANDING THE IMPACT OF NARCOLEPSY ON SOCIAL RELATIONSHIPS IN YOUNG ADULTS | JAZZ PHARMACEUTICALS INC. | $96,000 | 0 |
| SODIUM OXYBATE IN REFRACTORY REM SLEEP BEHAVIOUR DISORDER: A RANDOMISED CONTROLLED STUDY | JAZZ PHARMACEUTICALS INC. | $75,498 | 0 |
| WHAT IS SODIUM OXYBATES MECHANISM OF ACTION? | JAZZ PHARMACEUTICALS INC. | $74,845 | 0 |
| WHAT IS SODIUM OXYBATE'S MECHANISM OF ACTION? | Jazz Pharmaceuticals Inc. | $74,845 | 0 |
| UNDERSTANDING THE IMPACT OF NARCOLEPSY AND IDIOPATHIC HYPERSOMNIA IN YOUNG ADULTS | JAZZ PHARMACEUTICALS INC. | $67,593 | 0 |
| A RANDOMIZED DOUBLE-BLIND CONTROLLED TWO SITE STUDY COMPARING THE EFFICACY AND TOLERANCE OF SODIUM OXYBATE IN PATIENTS AFFECTED WITH IDIOPATHIC HYPERSOMNIA | JAZZ PHARMACEUTICALS INC. | $67,170 | 0 |
| EFFECT OF ANTIDEPRESSANTS ON SPLEEP ARCHITECTURE-FOCUS ON MSLT | JAZZ PHARMACEUTICALS INC. | $49,698 | 0 |
| EFFECT OF ANTIDEPRESSANTS ON SLEEP ARCHITECTURE | JAZZ PHARMACEUTICALS INC. | $49,698 | 0 |
| THE NEUROBEHAVIOURAL AND COGNITIVE EFFECTS OF DISRUPTED NIGHTIME SLEEP IN PEDIATRIC NARCOLEPSY | JAZZ PHARMACEUTICALS INC. | $26,964 | 0 |
| UNDERSTANDING THE IMPACT OF NARCOLEPSY AND IDIOPATHIC HYPERSOMNIA | JAZZ PHARMACEUTICALS INC. | $22,531 | 0 |
| A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF XYREM WITH AN OPEN-LABEL PHARMACOKINETIC EVALUATION AND SAFETY EXTENSION IN PEDIATRIC SUBJECTS WITH NARCOLEPSY WITH CATAPLEXY | JAZZ PHARMACEUTICALS INC. | $9,683 | 0 |
Top Doctors Receiving Payments for XYREM — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Neurology | Glenview, IL | $18,074 | 33 |
| , M.D | Neurology | Syracuse, NY | $17,820 | 27 |
| , MD | Critical Care Medicine | Paramus, NJ | $17,190 | 35 |
| , MD | Neurology | Chicago, IL | $17,039 | 13 |
| , MD | Hypertension Specialist | Farmington, CT | $15,406 | 2 |
| , MD | Pulmonary Disease | Cincinnati, OH | $15,324 | 15 |
| , M.D | Neurology | Richmond, VA | $14,551 | 30 |
| , M.D | Cardiovascular Disease | Elmhurst, IL | $14,363 | 10 |
| , MD | Cardiovascular Disease | Seattle, WA | $14,050 | 12 |
| , M.D | Pulmonary Disease | Chicago, IL | $13,828 | 21 |
| , MD | Neurology | Bronx, NY | $13,378 | 8 |
| , M.D | Neurology | Durham, NC | $12,745 | 18 |
| , M.D | Sleep Medicine | New York, NY | $12,514 | 18 |
| , MD | Psychiatry | Madison, WI | $11,500 | 2 |
| , MD | Critical Care Medicine | Cincinnati, OH | $11,278 | 33 |
| , M.D. F.C.C.P | Pulmonary Disease | Thousand Oaks, CA | $11,187 | 24 |
| , MD | Cardiovascular Disease | Philadelphia, PA | $10,473 | 9 |
| , MD | Pulmonary Disease | Charleston, SC | $10,046 | 18 |
| , M.D | Sleep Medicine | San Diego, CA | $8,907 | 18 |
| , M.D | Hematology & Oncology | Scottsdale, AZ | $8,638 | 3 |
| , M.D | Internal Medicine | Redwood City, CA | $8,294 | 18 |
| , M.D | Pulmonary Disease | Abington, PA | $8,100 | 1 |
| , M.D | Pulmonary Disease | Columbia, SC | $7,865 | 22 |
| , MD | Critical Care Medicine | San Diego, CA | $7,713 | 3 |
| , M.D | Neurology | Stanford, CA | $7,401 | 11 |
Ad
Manufacturing Companies
- JAZZ PHARMACEUTICALS INC. $3.0M
- Jazz Pharmaceuticals Inc. $516,188
Product Information
- Type Drug
- Total Payments $3.5M
- Total Doctors 3,953
- Transactions 11,960
About XYREM
XYREM is a drug associated with $3.5M in payments to 3,953 healthcare providers, recorded across 11,960 transactions in the CMS Open Payments database. The primary manufacturer is JAZZ PHARMACEUTICALS INC..
Payment data is available from 2019 to 2024. In 2024, $55,700 was paid across 83 transactions to 70 doctors.
The most common payment nature for XYREM is "Unspecified" ($1.5M, 43.2% of total).
XYREM is associated with 16 research studies, including "SODIUM OXYBATE IN REFRACTORY REM SLEEP BEHAVIOR DISORDER: A RANDOMIZED CONTROLLED STUDY" ($405,183).